Imdelltra with Imfinzi cuts risk of death 58% in small cell lung cancer
FROM THE WIRE · FINANCE.YAHOO.COM
Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPhase 3 results presented at ESMO may matter for Amgen and AstraZeneca.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The combination reduces risk of death by 58% as first-line maintenance.
- 02Nearly 80% of patients were alive at one year versus 53% with Imfinzi alone.
- 03The results were published in the New England Journal of Medicine.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Amgen Inc.439.26 USDMarket closedtoday -1.79%Positive AstraZeneca PLC171.49 USDMarket closedtoday -0.63%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets